Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways (original) (raw)
Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells
Ana-Maria Florea
Journal of Neurochemistry, 2012
View PDFchevron_right
Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51
Juan Jose Martinez Irujo, Marta Maria Alonso Roldan, Marta Alonso, Arlet Maria Acanda de la Rocha, Beatriz Vera
View PDFchevron_right
The SIAH1–HIPK2–p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death
Bernd Kaina
Molecular Cancer Research, 2019
View PDFchevron_right
MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma
Johan Kros
The New England Journal of Medicine, 2005
View PDFchevron_right
Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level
Jessian Munoz
Oncotarget, 2015
View PDFchevron_right
Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
Jack A Tuszynski
Oncotarget, 2017
View PDFchevron_right
Endoplasmic reticulum chaperone prolyl 4-hydroxylase, beta polypeptide (P4HB) promotes malignant phenotypes in glioma via MAPK signaling
Philip Day
Oncotarget, 2017
View PDFchevron_right
Cancer- related protein profile of patient-derived and commercial glioblastoma cell lines exposed to Temozolomide
Ewa Obuchowicz
Research Square (Research Square), 2023
View PDFchevron_right
The Combined Therapeutic Effects of Bortezomib and Fenretinide on Neuroblastoma Cells Involve Endoplasmic Reticulum Stress Response
Pastorino, Pastorino
Clinical Cancer Research, 2009
View PDFchevron_right
Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma
Jens Gempt
Neuro-Oncology, 2012
View PDFchevron_right
Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma
Lisa Oliver
Cell Death & Disease
View PDFchevron_right
Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib
jasim uddin
Cancer Research, 2008
View PDFchevron_right
Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
Marcela Latancia
Biomedicines
View PDFchevron_right
Expression of Endoplasmic Reticulum Stress Proteins Is a Candidate Marker of Brain Metastasis in both ErbB-2+ and ErbB-2− Primary Breast Tumors
Miguel Angel Garcia Gil
The American Journal of Pathology, 2011
View PDFchevron_right
Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma
Giacomo Signorino
Oncotarget, 2017
View PDFchevron_right
Multifaceted Resistance of Gliomas to Temozolomide1
Demetrius Kokkinakis
2002
View PDFchevron_right
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas
Francesca Garello
Neoplasia, 2017
View PDFchevron_right
Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain
Susan Nozell
Journal of Biological Chemistry, 2010
View PDFchevron_right
Involvement of PI3K Pathway in Glioma Cell Resistance to Temozolomide Treatment
Iwona Wertel
International Journal of Molecular Sciences
View PDFchevron_right
Investigation of serum proteome alterations in human glioblastoma multiforme
Koel Chaudhury
PROTEOMICS, 2012
View PDFchevron_right
Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study
Jannick Brennum
Molecular Oncology, 2021
View PDFchevron_right
Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD+ Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase
marie migaud
Cancers, 2022
View PDFchevron_right
Multifaceted resistance of gliomas to temozolomide
Demetrius Kokkinakis
Clinical cancer …, 2002
View PDFchevron_right
The contribution of proteoglycans to heterogeneity and temozolomide resistance of glioblastoma cells
Journal of Cancer Metastasis and Treatment, Elvira V. Grigorieva
Journal of Cancer Metastasis and Treatment, 2024
View PDFchevron_right
Epigenomic perturbation of novelEGFRenhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide
Itzel Nissen
bioRxiv (Cold Spring Harbor Laboratory), 2023
View PDFchevron_right
A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines
Marianna Pap
International Journal of Molecular Sciences
View PDFchevron_right
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo- …
Gianluca Bontempi
… (New York, NY), 2010
View PDFchevron_right
Targeting of endoplasmic reticulum (ER) stress in gliomas
Christina Piperi
Pharmacological Research, 2020
View PDFchevron_right